Danzi S, Klein I
Division of Endocrinology, Department of Medicine, North Shore University Hospital/NYU School of Medicine and North Shore LIJ Research Institute, Manhasset, NY 11030, USA.
Minerva Endocrinol. 2004 Sep;29(3):139-50.
Thyroid hormone is an important regulator of cardiac function and cardiovascular hemodynamics. Triiodothyronine, (T(3)), the physiologically active form of thyroid hormone, binds to nuclear receptor proteins and mediates the expression of several important cardiac genes, inducing transcription of the positively regulated genes including alpha-myosin heavy chain (MHC) and the sarcoplasmic reticulum calcium ATPase. Negatively regulated genes include beta-MHC and phospholamban, which are down regulated in the presence of normal serum levels of thyroid hormone. T(3) mediated effects on the systemic vasculature include relaxation of vascular smooth muscle resulting in decreased arterial resistance and diastolic blood pressure. In hyperthyroidism, cardiac contractility and cardiac output are enhanced and systemic vascular resistance is decreased, while in hypothyroidism, the opposite is true. Patients with subclinical hypothyroidism manifest many of the same cardiovascular changes, but to a lesser degree than that which occurs in overt hypothyroidism. Cardiac disease states are sometimes associated with the low T(3) syndrome. The phenotype of the failing heart resembles that of the hypothyroid heart, both in cardiac physiology and in gene expression. Changes in serum T(3) levels in patients with chronic congestive heart failure are caused by alterations in thyroid hormone metabolism suggesting that patients may benefit from T(3) replacement in this setting.
甲状腺激素是心脏功能和心血管血流动力学的重要调节因子。三碘甲状腺原氨酸(T₃)是甲状腺激素的生理活性形式,它与核受体蛋白结合并介导几种重要心脏基因的表达,诱导包括α-肌球蛋白重链(MHC)和肌浆网钙ATP酶等正调控基因的转录。负调控基因包括β-MHC和受磷蛋白,在甲状腺激素血清水平正常时它们会下调。T₃对全身血管系统的介导作用包括血管平滑肌舒张,导致动脉阻力和舒张压降低。甲状腺功能亢进时,心脏收缩力和心输出量增强,全身血管阻力降低;而甲状腺功能减退时则相反。亚临床甲状腺功能减退患者表现出许多相同的心血管变化,但程度比明显的甲状腺功能减退要轻。心脏疾病状态有时与低T₃综合征有关。衰竭心脏的表型在心脏生理学和基因表达方面都类似于甲状腺功能减退的心脏。慢性充血性心力衰竭患者血清T₃水平的变化是由甲状腺激素代谢改变引起的,这表明在这种情况下患者可能从T₃替代治疗中获益。